- Home
- SPOK vs CADL Comparison
SPOK vs CADL Comparison
Compare SPOK & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- CADL
- Stock Information
- Founded
- SPOK 2004
- CADL 1999
- Country
- SPOK United States
- CADL United States
- Employees
- SPOK N/A
- CADL N/A
- Industry
- SPOK Telecommunications Equipment
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- SPOK Telecommunications
- CADL Health Care
- Exchange
- SPOK Nasdaq
- CADL Nasdaq
- Market Cap
- SPOK 329.2M
- CADL 306.4M
- IPO Year
- SPOK 1992
- CADL 2021
- Fundamental
- Price
- SPOK $15.79
- CADL $8.75
- Analyst Decision
- SPOK Hold
- CADL Strong Buy
- Analyst Count
- SPOK 1
- CADL 4
- Target Price
- SPOK $15.00
- CADL $21.00
- AVG Volume (30 Days)
- SPOK 158.6K
- CADL 1.4M
- Earning Date
- SPOK 04-30-2025
- CADL 03-13-2025
- Dividend Yield
- SPOK 7.92%
- CADL N/A
- EPS Growth
- SPOK N/A
- CADL N/A
- EPS
- SPOK 0.73
- CADL N/A
- Revenue
- SPOK $137,653,000.00
- CADL N/A
- Revenue This Year
- SPOK $3.51
- CADL N/A
- Revenue Next Year
- SPOK N/A
- CADL N/A
- P/E Ratio
- SPOK $21.63
- CADL N/A
- Revenue Growth
- SPOK N/A
- CADL N/A
- 52 Week Low
- SPOK $13.24
- CADL $1.34
- 52 Week High
- SPOK $17.96
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- SPOK 37.61
- CADL 52.73
- Support Level
- SPOK $16.10
- CADL $7.65
- Resistance Level
- SPOK $16.86
- CADL $8.31
- Average True Range (ATR)
- SPOK 0.51
- CADL 0.92
- MACD
- SPOK -0.11
- CADL -0.10
- Stochastic Oscillator
- SPOK 8.44
- CADL 33.33
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.